Piper Sandler lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $163 from $166 and keeps an Overweight rating on the shares. The firm notes Jazz shares are down about 30% since the closing of the GW acquisition in May 2021, even with Epidiolex-associated diversification and the success of Xywav. Though Piper is bullish on the transformative potential of the OX2R agonists in sleep/wake, it still envisions a sizable role for oxybate products, particularly in narcolepsy type 2 and idiopathic hypersomnia, where orexin deficiency is not core to underlying disease pathophysiology. Put differently, with Jazz at an EV/2025 EBITDA of 5-times, the shares are trading as if there is a major loss of exclusivity on the horizon. However, “that is not where we are at,” the firm argues.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Zymeworks, Jazz Pharmaceuticals announce FDA approval of Ziihera
- Jazz Pharmaceuticals announces FDA approval of Ziihera in BTC
- Jazz Pharmaceuticals price target raised to $162 from $154 at Baird
- Biotech Alert: Searches spiking for these stocks today
- Jazz Pharmaceuticals price target lowered to $195 from $200 at TD Cowen